The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.

The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.

The goal of this program is to improve the knowledge, confidence, and competence of learners in the potential clinical applications of guideline-recommended therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Bruton’s tyrosine kinase inhibitors (BTKi) have significantly changed the treatment landscape of B-cell malignancies. A thorough understanding of the mechanism of action (covalent vs. non-covalent), similarities and differences in their safety profile and management of specific treatment-related adverse events will enable clinicians to use these agents safely and effectively in routine clinical practice.

There is a continuing need to educate clinicians about the emerging treatment options as this will aid in the successful implementation of more effective treatment options in routine clinical setting.

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.